Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Leflunomide in Patients With High-Risk Smoldering Multiple Myeloma

NCT03952832 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03952832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03952832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Leflunomide in Patients With High-Risk Smoldering Multiple Myeloma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Withdrawn
Start date
December 11, 2019
Completion date
June 11, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

smoldering plasma cell myeloma